PT - JOURNAL ARTICLE AU - Roel, Elena AU - Pistillo, Andrea AU - Recalde, Martina AU - Sena, Anthony G. AU - Fernández-Bertolín, Sergio AU - Aragón, María AU - Puente, Diana AU - Ahmed, Waheed-Ul-Rahman AU - Alghoul, Heba AU - Alser, Osaid AU - Alshammari, Thamir M. AU - Areia, Carlos AU - Blacketer, Clair AU - Carter, William AU - Casajust, Paula AU - Culhane, Aedin C. AU - Dawoud, Dalia AU - DeFalco, Frank AU - Duvall, Scott L. AU - Falconer, Thomas AU - Golozar, Asieh AU - Gong, Mengchun AU - Hester, Laura AU - Hripcsak, George AU - Tan, Eng Hooi AU - Jeon, Hokyun AU - Jonnagaddala, Jitendra AU - Lai, Lana Y.H. AU - Lynch, Kristine E. AU - Matheny, Michael E. AU - Morales, Daniel R. AU - Natarajan, Karthik AU - Nyberg, Fredrik AU - Ostropolets, Anna AU - Posada, José D. AU - Prats-Uribe, Albert AU - Reich, Christian G. AU - Rivera, Donna AU - Schilling, Lisa M. AU - Soerjomataram, Isabelle AU - Shah, Karishma AU - Shah, Nigam AU - Shen, Yang AU - Spotniz, Matthew AU - Subbian, Vignesh AU - Suchard, Marc A. AU - Trama, Annalisa AU - Zhang, Lin AU - Zhang, Ying AU - Ryan, Patrick AU - Prieto-Alhambra, Daniel AU - Kostka, Kristin AU - Duarte-Salles, Talita TI - Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain AID - 10.1101/2021.01.12.21249672 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.12.21249672 4099 - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249672.short 4100 - http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249672.full AB - Purpose We aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.Methods We conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.Results We included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events.Conclusion Patients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Mr. Sena reports personal fees from Janssen Research & Development, outside the submitted work; Dr. DuVall reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research, outside the submitted work; Mr Ahmed reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England; Dr. Golozar reports personal fees from Regeneron Pharmaceuticals, outside the submitted work. She is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), outside the submitted work; Dr. Jonnagaddala reports grants from National Health and Medical Research Council, outside the submitted work; Dr. Nyberg reports other from AstraZeneca, outside the submitted work; Dr. Subbian reports grants from National Science Foundation, grants from State of Arizona; Arizona Board of Regents, grants from Agency for Healthcare Research and Quality, outside the submitted work; Dr Prieto-Alhambra reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA's department and open for external participants. Ms. Kostka and Dr. Reich report being employees of IQVIA Inc. Dr. Ryan is an employee of Janssen Research and Development and shareholder of Johnson & Johnson. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. No other relationships or activities that could appear to have influenced the submitted work. Disclaimer Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.Funding StatementThis project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]; Bill & Melinda Gates Foundation (INV-016201); and the Direccio General de Recerca i Innovacio en Salut from the Department of Health of the Generalitat de Catalunya. WURA reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England. LH, AGS are employed by Janssen Research and Development, LLC. JJ reports grants from the National Health and Medical Research Council (APP1192469). MG & YZ reports grants from National Key Research & Development Program of China (Project No. 2018YFC0116901). VS reports funding from the National Science Foundation, Agency for Health Care Research & Quality, National Institute of Health, and the State of Arizona. AP-U is supported by Fundacion Alfonso Martin Escudero and the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1). No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, Department of Veterans Affairs or the United States Government, NHS or the Department of Health, England. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the data partners received Institutional Review Board (IRB) approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-53248) registered to Leland Stanford Junior University under the Stanford Human Research Protection Program (HRPP). The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. SIDIAP analyses were approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). Approval for CPRD was provided by the Independent Scientific Advisory Committee (ISAC). For IQVIA-OpenClaims, approval is provided for OHDSI community studies. This is a retrospective database study on de-identified data and it is deemed not human subject research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOpen Science is a guiding principle within OHDSI.  As such, we provide unfettered access to all open-source analysis tools employed in this study via https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis, as well as all data and results artefacts that do not include patient-level health information via https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Data partners contributing to this study remain custodians of their individual patient-level health information and hold either IRB exemption or approval for participation. https://data.ohdsi.org/Covid19CharacterizationCharybdis/ ARDSAcute Respiratory Distress Syndrome;CDMCommon Data Model;CHARYBDISCharacterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2;CIConfidence Interval;COPDChronic Obstructive Pulmonary Disease:COVID-19Coronavirus disease 2019;CU-AMC-DHCColorado University Anschutz Medical Campus Health Data Compass;CUIMCColumbia University Irving Medical Center;EHRElectronic Health Record;EHRElectronic Health Record;IRBInstitutional Review Board;OHDSIObservational Health Data Sciences and Informatics;HAIHealthcare-associated infection;OMOPObservational Medical Outcomes Partnership;NHLNon-Hodgkin’s lymphoma;SARS-CoV-2Severe Acute respiratory Syndrome Coronavirus-2;SIDIAPInformation System for Research in Primary Care;SMDStandardized Mean Differences;SNOMEDSystematized Nomenclature of Medicine;STARR-OMOPStanford Medicine Research Data Repository;UKUnited Kingdom;USUnited States;VA-OMOPUnited States Department of Veterans Affairs.